These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 23197772)

  • 1. In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder.
    Barth V; Need AB; Tzavara ET; Giros B; Overshiner C; Gleason SD; Wade M; Johansson AM; Perry K; Nomikos GG; Witkin JM
    J Pharmacol Exp Ther; 2013 Feb; 344(2):501-10. PubMed ID: 23197772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A.
    Reavill C; Taylor SG; Wood MD; Ashmeade T; Austin NE; Avenell KY; Boyfield I; Branch CL; Cilia J; Coldwell MC; Hadley MS; Hunter AJ; Jeffrey P; Jewitt F; Johnson CN; Jones DN; Medhurst AD; Middlemiss DN; Nash DJ; Riley GJ; Routledge C; Stemp G; Thewlis KM; Trail B; Vong AK; Hagan JJ
    J Pharmacol Exp Ther; 2000 Sep; 294(3):1154-65. PubMed ID: 10945872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo.
    Millan MJ; Svenningsson P; Ashby CR; Hill M; Egeland M; Dekeyne A; Brocco M; Di Cara B; Lejeune F; Thomasson N; Munoz C; Mocaër E; Crossman A; Cistarelli L; Girardon S; Iob L; Veiga S; Gobert A
    J Pharmacol Exp Ther; 2008 Feb; 324(2):600-11. PubMed ID: 18024787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonist-induced yawning in rats: a dopamine D3 receptor-mediated behavior.
    Collins GT; Witkin JM; Newman AH; Svensson KA; Grundt P; Cao J; Woods JH
    J Pharmacol Exp Ther; 2005 Jul; 314(1):310-9. PubMed ID: 15833897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dopamine D4 receptor-selective antagonists on motor hyperactivity in rats with neonatal 6-hydroxydopamine lesions.
    Zhang K; Davids E; Tarazi FI; Baldessarini RJ
    Psychopharmacology (Berl); 2002 Apr; 161(1):100-6. PubMed ID: 11967637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat.
    Stemp G; Ashmeade T; Branch CL; Hadley MS; Hunter AJ; Johnson CN; Nash DJ; Thewlis KM; Vong AK; Austin NE; Jeffrey P; Avenell KY; Boyfield I; Hagan JJ; Middlemiss DN; Reavill C; Riley GJ; Routledge C; Wood M
    J Med Chem; 2000 May; 43(9):1878-85. PubMed ID: 10794704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of dopamine D(3) receptors in frontal cortex, but not in sub-cortical structures, enhances social recognition in rats: similar actions of D(1) receptor agonists, but not of D(2) antagonists.
    Loiseau F; Millan MJ
    Eur Neuropsychopharmacol; 2009 Jan; 19(1):23-33. PubMed ID: 18793829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of dopamine D3 receptors in the expression of conditioned fear in rats.
    Swain SN; Beuk J; Heidbreder CA; Beninger RJ
    Eur J Pharmacol; 2008 Jan; 579(1-3):167-76. PubMed ID: 17996231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats.
    Gyertyán I; Sághy K
    Eur J Pharmacol; 2007 Oct; 572(2-3):171-4. PubMed ID: 17628535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylphenidate normalizes elevated dopamine transporter densities in an animal model of the attention-deficit/hyperactivity disorder combined type, but not to the same extent in one of the attention-deficit/hyperactivity disorder inattentive type.
    Roessner V; Sagvolden T; Dasbanerjee T; Middleton FA; Faraone SV; Walaas SI; Becker A; Rothenberger A; Bock N
    Neuroscience; 2010 Jun; 167(4):1183-91. PubMed ID: 20211696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphetamine decreases behavioral inhibition by stimulation of dopamine D2, but not D3, receptors.
    van Gaalen MM; Unger L; Jongen-Rêlo AL; Schoemaker H; Gross G
    Behav Pharmacol; 2009 Sep; 20(5-6):484-91. PubMed ID: 19696659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locomotor activity induced by MK-801 is enhanced in dopamine D3 receptor knockout mice but suppression by dopamine D3/D2 antagonists does not occur through the dopamine D3 receptor.
    Yarkov AV; Der TC; Joyce JN
    Eur J Pharmacol; 2010 Feb; 627(1-3):167-72. PubMed ID: 19900441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SB-277011 GlaxoSmithKline.
    Remington G; Kapur S
    Curr Opin Investig Drugs; 2001 Jul; 2(7):946-9. PubMed ID: 11757796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity.
    Jucaite A; Fernell E; Halldin C; Forssberg H; Farde L
    Biol Psychiatry; 2005 Feb; 57(3):229-38. PubMed ID: 15691523
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine D3 receptor antagonists as therapeutic agents.
    Joyce JN; Millan MJ
    Drug Discov Today; 2005 Jul; 10(13):917-25. PubMed ID: 15993811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine.
    Tzavara ET; Bymaster FP; Overshiner CD; Davis RJ; Perry KW; Wolff M; McKinzie DL; Witkin JM; Nomikos GG
    Mol Psychiatry; 2006 Feb; 11(2):187-95. PubMed ID: 16231039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.
    Millan MJ; Loiseau F; Dekeyne A; Gobert A; Flik G; Cremers TI; Rivet JM; Sicard D; Billiras R; Brocco M
    J Pharmacol Exp Ther; 2008 Mar; 324(3):1212-26. PubMed ID: 18096759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Habituation deficits induced by metabotropic glutamate receptors 2/3 receptor blockade in mice: reversal by antipsychotic drugs.
    Bespalov A; Jongen-Rêlo AL; van Gaalen M; Harich S; Schoemaker H; Gross G
    J Pharmacol Exp Ther; 2007 Feb; 320(2):944-50. PubMed ID: 17135347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.
    Bymaster FP; Golembiowska K; Kowalska M; Choi YK; Tarazi FI
    Synapse; 2012 Jun; 66(6):522-32. PubMed ID: 22298359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute neurobehavioral effects of toluene: involvement of dopamine and NMDA receptors.
    Lo PS; Wu CY; Sue HZ; Chen HH
    Toxicology; 2009 Nov; 265(1-2):34-40. PubMed ID: 19765629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.